BDD Receives Grant of $2 million to Develop Early-Stage Clinical Research

Archangels, a group of angel investors and Scottish Enterprise were among the existing supporters as well as a new advocate, British Business Bank.

According to BDD, it will be possible to conduct Phase I clinical trials of new drugs, enabling manufacturing and trials that will speed up the introduction of cutting-edge medications.

Professor Carol Thomson, Head of BDD stated, “More and more we are talking with companies who are developing the most exciting ground-breaking new medicines, but their path to market is being hampered by traditionally slow and costly development processes.”

The business disclosed that it had increased its revenues twofold compares to the year before and had signed agreements for 2023 and 2024 with significant pharmaceutical and biotech firms.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved